Femasys says FDA OKs modular PMA pathway for FemBloc birth control device

• FDA cleared Femasys to use a modular PMA submission pathway for FemBloc, its investigational non-surgical permanent birth control device.
• The structure allows FDA review of submission modules ahead of final clinical data, potentially speeding the route to a US marketing decision.
• FemBloc is already marketed in Europe and select international markets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Femasys Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608190900PRIMZONEFULLFEED9812507) on August 19, 2026, and is solely responsible for the information contained therein.